Stainless Steel Particle Risk Prompts Baxter Dextrose Injection Recall 2026

Baxter International Inc. has voluntarily recalled one lot of its 70% Dextrose Injection after discovering that select units may contain stainless steel particulate matter, the U.S. Food and Drug Administration announced on August 25, 2026. The Deerfield, Illinois-based manufacturer said the affected solution was shipped to healthcare providers and distributors in a handful of states between July 25 and July 28, 2026.

The product involved is 70% Dextrose Injection, USP, packaged in a 2000 mL VIAFLEX Plastic Container and sold as a Pharmacy Bulk Package, not intended for direct infusion. Hospitals and homecare providers use it as a source of calories and fluid replenishment, typically mixing it with amino acids or other compatible intravenous fluids to support patients who cannot get adequate nutrition orally or enterally.

• Lot Number: Y495066
• Product Code: 2B0296H
• NDC Number: 0338-0719-06
• Expiration Date: July 31, 2027
• Distribution Window: July 25-28, 2026
• States Affected: Alabama, Georgia, Tennessee

Products Affected by This Recall

Only one lot is impacted by this action. The affected units carry lot number ‘Y495066’, product code ‘2B0296H’, an expiration date of July 31, 2027, and NDC number ‘0338-0719-06’. Each case contains six units of the 2000 mL bag, and the lot number and expiration date are printed on both the individual product bags and the outer shipping cartons, allowing facilities to verify whether their stock is part of the recall.

Why Was This Recall Issued?

Baxter initiated the recall after identifying the potential presence of stainless steel particles within the dextrose solution. According to the company’s risk statement, intravenous administration of a product containing this kind of particulate matter could cause blockages and clotting in blood vessels, cutting off circulation to vital organs. In more severe cases, the particles could trigger a life-threatening pulmonary embolism or lead to permanent organ damage or death. The particles could also cause local vein irritation, inflammatory reactions, or worsen existing infections and allergic responses. Baxter said that, as of August 25, 2026, it had not received any reports of adverse events tied to the affected lot.

Where Were These Products Sold?

The recalled dextrose injection was shipped to a limited number of healthcare providers and distributors in select states, including Alabama, Georgia, and Tennessee, during the last week of July 2026. Because the product is used almost exclusively in clinical and homecare nutrition settings rather than sold directly to consumers, the recall primarily concerns hospitals, infusion pharmacies, and patients receiving compounded parenteral nutrition at home.

Steps Consumers Should Take

Healthcare facilities that received the affected lot are being told to immediately stop using it and return all remaining units according to their internal recall procedures. Baxter is reaching out to customers directly by email with instructions for identifying and returning the impacted product.

Homecare providers who used lot Y495066 to compound parenteral nutrition solutions are being asked to contact their patients right away, instructing them to stop using those compounded solutions and switch to replacements made from unaffected stock. Anyone who believes they or a patient in their care may have experienced a problem connected to this product should contact a physician or healthcare provider immediately. Questions about the recall can be directed to Baxter Healthcare Center for Service at 888-229-0001, available Monday through Friday from 7:00 a.m. to 6:00 p.m. Central Time.

Adverse events or quality issues linked to the product can also be reported to the FDA’s MedWatch program online, by mail, or by fax using the agency’s standard reporting form.

Official Statement

In its announcement, Baxter said it is ‘voluntarily recalling one lot of 70% Dextrose Injection due to the potential presence of particulate matter identified as stainless steel particles in the solution.’ The company confirmed that the FDA has been notified of the action and that it continues to work with affected customers to ensure the recalled lot is removed from use.